RNAZ (TransCode Therapeutics) EPS (Basic) : $-1,063.68 (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is TransCode Therapeutics EPS (Basic)?

TransCode Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-70.28. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1,063.68.

TransCode Therapeutics's EPS (Diluted) for the three months ended in Mar. 2025 was $-70.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1,063.68.

TransCode Therapeutics's EPS without NRI for the three months ended in Mar. 2025 was $-16.51. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -971.18.

During the past 3 years, the average EPS without NRI Growth Rate was 85.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 43.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, TransCode Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 85.40% per year. The lowest was -232.40% per year. And the median was 42.90% per year.

TransCode Therapeutics EPS (Basic) Historical Data

The historical data trend for TransCode Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransCode Therapeutics EPS (Basic) Chart

TransCode Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-146,493.31

-402,552.88

-1,033,233.41

-27,313.84

-1,319.92

TransCode Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial															-597.80	-683.76	-147.84	-161.80	-70.28

TransCode Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

TransCode Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-16.755	-	0)	/	0.013
	=	-1,288.85

TransCode Therapeutics's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-12.085	-	0)	/	0.172
	=	-70.26

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,063.68

TransCode Therapeutics (NAS:RNAZ) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

TransCode Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of TransCode Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

TransCode Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Liberty Square, No. 2382, Boston, MA, USA, 02109

Website

https://www.transcodetherapeutics.com

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Executives

Robert Michael Dudley	director, 10 percent owner, officer: Chief Executive Officer	C/O TRANSCODE THERAPEUTICS, 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Thomas A Fitzgerald	director, officer: VP, Chief Financial Officer	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Philippe Calais	director	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Anna Moore	10 percent owner	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Zdravka Medarova	10 percent owner	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Erik Manting	director	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109